After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney ...

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RARE), a biopharmaceutical company focused on the development of ...

The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.

A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small ...

Ahmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research ...

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis.

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

The UT administration's Drugs Control Wing conducted extensive raids on chemist shops in Manimajra, uncovering violations including unlicensed drug sales and absence of qualified pharmacists.

Chronic kidney disease, which affects over 10% of the global population, leads to a gradual decline in kidney function and can result in kidney failure.